Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 4 Interventional Results available

Safety Study of Escitalopram in Children 7 to 11 Years of Age With Major Depressive Disorder

ClinicalTrials.gov ID: NCT01198795

Public ClinicalTrials.gov record NCT01198795. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 27, 2026, 12:20 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

An Open-label Long-term Study of Escitalopram in Children 7 to 11 Years of Age With Major Depressive Disorder

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This study will evaluate the long-term safety and tolerability of escitalopram (Lexapro) in children 7 to 11 years of age with major depressive disorder (MDD).

Study identification

NCT ID
NCT01198795
Recruitment status
Completed
Study type
Interventional
Phase
Phase 4
Lead sponsor
Forest Laboratories
Industry
Enrollment
162 participants

Conditions and interventions

Interventions

Drug

Eligibility (public fields only)

Age range
7 Years to 11 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Aug 31, 2010
Primary completion
Dec 31, 2012
Completion
Mar 31, 2013
Last update posted
Mar 13, 2014

2010 – 2013

United States locations

U.S. sites
16
U.S. states
14
U.S. cities
16
Facility City State ZIP Site status
Forest Investigative Site 001 Dothan Alabama 36303 —
Forest Investigative Site 006 San Diego California 92108 —
Forest Investigative Site 018 Santa Ana California 92701 —
Forest Investigative Site 008 Washington D.C. District of Columbia 20010-2970 —
Forest Investigative Site 013 Jacksonville Beach Florida 32250 —
Forest Investigative Site 017 Atlanta Georgia 30308 —
Forest Investigative Site 004 Overland Park Kansas 66211 —
Forest Investigative Site 011 Creve Coeur Missouri 63141 —
Forest Investigative Site 007 Omaha Nebraska 68131 —
Forest Investigative Site 002 Cleveland Ohio 44106 —
Forest Investigative Site 012 Oklahoma City Oklahoma 73116 —
Forest Investigative Site 003 Philadelphia Pennsylvania 19139 —
Forest Investigative Site 010 Dallas Texas 75235 —
Forest Investigative Site 014 Clinton Utah 84015 —
Forest Investigative Site 005 Bellevue Washington 98007 —
Forest Investigative Site 015 Kirkland Washington 98033 —

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT01198795, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Mar 13, 2014 · Synced Sep 27, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT01198795 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →